A Comparison of Agents Used to Manage Type 2 Diabetes Mellitus: Need for Reappraisal of Traditional Approaches

Treatments in Endocrinology

Volumn 3, Issue 2, 2004, Pages 67-76

  Bell, David S H ^a,b  

^a University of Alabama at Birmingham   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CALCIUM; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL CRAMP; ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SYNTHESIS; LACTIC ACIDOSIS; MICROANGIOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; OUTCOMES RESEARCH; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT FAILURE; VASCULAR DISEASE; WEIGHT GAIN;

ALPHA-GLUCOSIDASES; ANIMALS; BENZAMIDES; BIGUANIDES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 1542725012     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403020-00001     Document Type: Review

References (94)

1. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9
2. Iwamoto Y, Kosaka K, Kuzuya J, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-6
3. Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes: the Troglitazone Study Group. Diabetes Care 1998; 21: 1462-9
4. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-8
5. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-21
6. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4
7. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92
8. Olsson J, Lindberg G, Gottsäter M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-60
9. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-8
10. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25 Suppl. 1: S33-49
11. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. The UK Prospective Diabetes Study Group. BMJ 2000; 321: 405-12
12. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-8
13. ACE guidelines: American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002; 8 Suppl. 1: 6-11
14. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
15. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
16. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999; 7: 139-53
17. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-9
18. Tian Y-M, Johnson G, Ashcroft SJH. Sulfonylureas enhance exocytosis from pancreatic β-cells by a mechanism that does not involve direct activation of protein kinase C. Diabetes 1998; 47: 1722-6
19. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-61
20. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-85
21. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract 2001; 7: 135-8
22. Yang W-S, Jeng C-Y, Wu T-J, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-80
23. Chandran M, Phillips S, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-8
24. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity-induced β cell disease. J Clin Invest 1997; 100: 290-5
25. Shimabukuro M, Koyama K, Lee Y, et al. Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1β cytotoxicity. J Clin Invest 1997;
26. Finegood DT, McArthur MD, Kojwang D, et al. β-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-9
27. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes [abstract]. Diabetes 2000; 49 Suppl. 1: A122
28. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998; 4: 146-7
29. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 271-5.
30. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone [letter]. Endocr Pract 2001; 7: 326
31. Dandona P, Aljada A, Chaudhuri A, et al. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2422-9
32. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-65
33. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab 2001; 86: 3250-6
34. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-12
35. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84
36. Torzewski M, Rist C, Montensen RF, et al. C-Reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-9
37. phox subunit expression in mononuclear cells (MNC) and reduces C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect [abstract]. Diabetes 2001; 50 Suppl. 2: A68
38. Law RE, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311-8
39. Takagi T, Akasaka T, Yamamoto A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-35
40. Choi SH, Choi DH, Ko YK, et al. Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes [abstract]. Diabetes 2003; 52 Suppl. 1: A19
41. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-20
42. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-6
43. Bakris GL, Dole JF, Porter LE, et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus [abstract]. Diabetes 2000; 49 Suppl. 1: A96
44. Ovalle F, Bell DSH. Differing effects of thiazolidinediones on HDL subfractions and Lp(a) [abstract]. Diabetes 2001; 50 Suppl. 2: A461-2
45. Winkler K, Konrad T, Fuellert S, et al. Pioglitazone selectively reduces dense LDL: a placebo controlled trial in hypertensive patients [poster]. The 38th Annual Meeting of the European Association for the Study of Diabetes; 2002 Sep 4, Budapest
46. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract 2002; 8: 406-10
47. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities of type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-52
48. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12: 1496-502
49. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 Suppl. 1: 20-3
50. McTernan PG, Eggo MC, Smith SA, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes [abstract]. Diabetes 2001; 50 Suppl. 2: A275
51. Kohler HP, Grant P. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801
52. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-21
53. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7
54. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4
55. Williams SB, Cusco JA, Roddy M-A, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-74
56. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17: 7-12
57. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-9
58. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14: 250-4
59. Bell DSH, Ovalle F. Metformin lowers lipoprotein(a) levels [letter]. Diabetes Care 1998; 21: 2028
60. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72
61. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93
62. Spivak JL. Erythropoietin use and abuse: when physiology and pharmacology collide. In: Roach RC, Wagner PD, Hackett PH, editors. Hypoxia: from genes to the bedside. New York: Kluwer Academic/Plenum Publishers, 2001: 207-24
63. Baba T, Shimada K, Neugebauer S, et al. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001; 24: 953-4
64. Eto K, Ohya Y, Nakamura Y, et al. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 2001; 423: 1-7
65. Viberti G, Kahn S, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-43
66. Perfetti R, Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. Trends Endocrinol Metab 2000; 11: 218-23
67. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-22
68. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54
69. Jovanovic L, Dailey III G, Huang W-C, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57
70. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-57
71. Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-77
72. Goldberg RB, Einhom D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-903
73. Bell DSH, Yumuk VD. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract 1997; 3: 281-3
74. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in type 2 diabetic patients treated with glimepiride versus glibenclamide [abstract]. Diabetologia 2000; 43 Suppl. 1: A40
75. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 2000; 93: 369-74
76. Bautista JL, Bugos C, Dimberger G, et al. The efficacy and safety of Amaryl as compared to placebo in Mexican-Americans with type 2 diabetes inadequately controlled by exercise and diet alone [abstract]. Diabetes Res Clin Pract 2000; 50 Suppl. 1: S46
77. Glucophage prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2001
78. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
79. Chu NV, Kong APS, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25: 542-9
80. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
81. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-7
82. Glucophage XR prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2001
83. 12 malabsorption induced by metformin. Diabetes Care 2000; 23: 1227-31
84. Wiholm B-E, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44: 589-91
85. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985; 15 Suppl.: 105-11
86. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin [letter]. N Engl J Med 1998; 338: 265-6
87. Lebovitz HE. A new oral therapy for diabetes management: alpha-glucosidase inhibition with acarbose. Clin Diabetes 1995; 13: 99-103
88. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
89. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The STOP-NIDDM Trial Research Group. Lancet 2002; 359: 2072-7
90. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997; 20: 687-91
91. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154: 2442-8
92. Glyset prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Company, 2001
93. Precose prescribing information. West Haven (CT): Bayer Corporation Pharmaceutical Division, 2001
94. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657-62